Every 424B that EyePoint (EYPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EYPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EYPT filings page.
EyePoint Pharmaceuticals (EYPT) launched an at-the-market offering of up to $200,000,000 in common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. Shares may be sold from time to time in transactions deemed “at the market offerings” under Rule 415(a)(4), including sales on The Nasdaq Global Market. Cantor will act as sales agent and receive a fixed commission equal to 3.0% of the aggregate gross sales price per share sold.
The company states it intends to use net proceeds to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs leveraging its Durasert E technology, and for general corporate purposes. The common stock trades on Nasdaq under “EYPT”; the last reported sale price was $12.45 on November 3, 2025.
EyePoint Pharmaceuticals launched a primary offering of 11,000,000 shares of common stock and pre-funded warrants for 1,500,000 shares at $12.00 per share and $11.999 per warrant.
The deal is expected to generate approximately $140.7 million in net proceeds, with a 30-day option for underwriters to purchase up to 1,875,000 additional shares. Management plans to use the funds to advance Phase 3 development of DURAVYU for wet AMD and DME, support earlier-stage programs, and for general corporate purposes. The company states these resources, together with existing cash, are expected to fund operations into the fourth quarter of 2027, beyond anticipated wet AMD topline data in 2026.
The pre-funded warrants carry a $0.001 exercise price and may be exercised for shares; there will be no public market for these warrants.
EyePoint Pharmaceuticals (EYPT) launched a primary offering of $150,000,000 of common stock via a prospectus supplement, with underwriters granted a 30‑day option to purchase up to an additional $22,500,000 at the public offering price, less underwriting discounts and commissions.
The company’s common stock trades on Nasdaq Global Market under “EYPT.” Estimated net proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes. EyePoint estimated approximately $200 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company states that existing cash plus expected net proceeds should fund operations into the fourth quarter of 2027.
Recent updates note DURAVYU’s Phase 3 program initiation planning in DME and ongoing Phase 3 trials in wet AMD. As context, shares outstanding were 68,889,649 as of June 30, 2025, plus 825,844 shares issued under an at‑the‑market program through October 6, 2025. A 60‑day lock‑up applies to the company and insiders, with specified exceptions.